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We read with great interest the article by Tarvasmäki
et al. [1], who observed the relationship between vasopres-
sor/inotrope use and outcome in patients with cardiac
shock (CS). Their results indicate that use of adrenaline in
CS is associated with increased 90-day mortality and
marked worsening of cardiac and renal biomarkers during
the first few days. The study underscores the need
for randomized controlled trials of adrenaline versus
noradrenaline in CS.
However, we have to raise a serious question regarding
the undetailed subgroup of patients with cardiac arrest
(CA) because we consider that those CA patients should
have been excluded from this study or at least should be
analyzed in the form of a subgroup. According to their
results, 39 % of patients received adrenaline prior to in-
clusion because of CA. After inclusion, 21 % of patients
received adrenaline. We doubt whether the “21 %” were
mainly those who suffered from CA. This is of vital im-
portance because it may cause an obvious bias. This is
true when we review their data. Their Table 1 explicitly
indicates that patients treated with adrenaline had more
severe complications with higher proportions of confusion,
oliguria, and hyperlactacidemia. However, a large number
of CA patients can also present with confusion, oliguria,
and hyperlactacidemia if they experience a prolonged low-
flow or no-flow state. Therefore, it should be realized that
the CA patients were inappropriately included.
Adrenaline use is associated with higher oxygen re-
quirements of the heart [2]. The very recent European
and American guidelines for the diagnosis and treatment
of acute heart failure do not recommend routine use
of adrenaline in CS unless patients have persistent
hypotension despite adequate cardiac filling pressures
and the use of other vasoactive agents and resuscitation
[3, 4]. The use of noradrenaline has been prevalent in
the management of critically ill patients and has been
given high grade recommendations in guidelines. Thus,
we do not think further clinical trials are required to
compare adrenaline and noradrenaline for the treatment
of CS.
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We thank Zhao and colleagues for their interest in our
paper. We agree that showing the results of survival ana-
lyses excluding resuscitated patients may be of additional
value. Hence, in the subgroup of patients that were not re-
suscitated, the adjusted 90-day mortality odds ratio for
adrenaline (versus other vasopressors) was 6.5 (95 % con-
fidence interval 1.5–27.2, p = 0.01). Figure S2 (Additional
file 5) in our original paper [1] confirms the detrimental
evolution of cardiac and renal biomarkers in patients
treated with adrenaline versus other vasopressors in the
subgroup of non-resuscitated patients.
While subgroup analyses in the non-resuscitated pa-
tients consistently showed that adrenaline was associated
with detrimental effects on outcome, we prefer to present
the results for the whole cohort—not specifically exclud-
ing patients who had cardiac arrest—as resuscitated pa-
tients are part of our daily practice. Indeed, a significant
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proportion of patients (28 % in the CardShock study) with
cardiogenic shock are resuscitated.
We would also take the opportunity to clarify the num-
bers regarding the frequency of adrenaline use. Of all pa-
tients included in the study, 21 % (46/216) were treated
with adrenaline, defined as the use of continuous infusion
(not bolus injection related to, e.g., resuscitation). However,
less than half of the patients treated with continuous adren-
aline, 39 % (18/46), were resuscitated prior to study inclu-
sion. On the other hand, 70 % of resuscitated patients were
not treated later with continuous adrenaline.
It is true that confusion, oliguria, and elevated lactate
levels are very common after cardiac arrest, reflecting in-
adequate organ perfusion also in this scenario. Neverthe-
less, signs of hypoperfusion are clinical landmark signs
of cardiogenic shock, with or without prior resuscitation.
The recently published European guidelines [3] recom-
mend rather restrictive use of adrenaline in the setting of
cardiogenic shock, but the level of evidence is low. The
latter might explain the surprisingly common use of adren-
aline. Moreover, there are no large randomized studies
supporting the recommendation to prefer noradrenaline
over adrenaline in CS. Altogether, we still believe that there
is room for a pivotal trial to identify the most efficient drug
regimen with a favorable safety profile in CS.
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